Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560485 | 1.00 | CYP2A6 (0.35) | CYP2A6GPR35PRKDCPRKCI | |
| SCHEMBL28715107 | 0.73 | GPR35 (0.45) | GPR35 | |
| SCHEMBL22866911 | 0.72 | CD38 (0.39) | GPR35PRKCI | |
| SCHEMBL22866921 | 0.71 | MAPT (0.33) | GPR35PRKCI | |
| SCHEMBL22866808 | 0.70 | CCR1 (0.47) | CYP2A6PRKCI | |
| SCHEMBL29560590 | 0.70 | CCR1 (0.47) | CYP2A6PRKCI | |
| SCHEMBL29560054 | 0.70 | KDM4E (0.39) | GPR35 | |
| SCHEMBL22866725 | 0.70 | KDM4E (0.39) | GPR35 | |
| SCHEMBL19554995 | 0.70 | PRKCI (0.36) | GPR35PRKCI | |
| SCHEMBL22866471 | 0.68 | L3MBTL1 (0.34) | GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269756-B | 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E | 效应疗法股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230108594-A1 | EIF4E-INHIBITING COMPOUNDS AND METHODS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-04-06 | — | — | US | disclosed |
| EP-3994139-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | Effector Therapeutics Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114269756-A | 4-oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds inhibiting EIF4E | 效应疗法股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11286268-B1 | EIF4E-inhibiting compounds and methods | EFFECTOR THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286268-B1 | EIF4E-inhibiting compounds and methods | EIF4E, EIF4EBP1, EIF4A1 | CYP2A6 3608/4885GPR35 4101/4885PRKDC 1350/4885 |
| US-20230108594-A1 | EIF4E-INHIBITING COMPOUNDS AND METHODS | EIF4E, EIF4EBP1, EIF4A1 | CYP2A6 3608/4885GPR35 4101/4885PRKDC 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.